Press/Media
- 13 results
Search results
-
EMPOWER reflects efficacy, safety of lanadelumab for HAE in real world
7/03/22
1 item of Media coverage
Press/Media
-
Interim Phase 4 Data Support TAKHZYRO® (lanadelumab) as an Effective Treatment to Reduce Attacks in Hereditary Angioedema Patients
27/02/22 → 2/03/22
39 items of Media coverage
Press/Media
-
-Takeda - Interim Phase 4 Data Support TAKHZYRO (lanadelumab) as an Effective Treatment to Reduce Attacks in Hereditary Angioedema Patients
1/03/22
2 items of Media coverage
Press/Media
-
Interim Phase 4 Data Support TAKHZYRO® (lanadelumab) as an Effective Treatment to Reduce ...
28/02/22
7 items of Media coverage
Press/Media
-
Takeda: Interim Phase 4 Data Support TAKHZYRO (lanadelumab) as an Effective Treatment
28/02/22
1 item of Media coverage
Press/Media
-
UAE - Interim Phase 4 Data Support TAKHZYRO® (lanadelumab) as an Effective Treatment to Reduce Attacks in Hereditary Angioedema Patients
28/02/22
1 item of Media coverage
Press/Media
-
NIH Establishes New Childhood Asthma Clinical Research Network
23/04/21 → 30/04/21
5 items of Media coverage
Press/Media
-
Children's National Hospital Becomes Part of the National CAUSE Clinical Research Network Under a $3 Million Grant
Paula Busse & Supinda Bunyavanich
27/04/21
1 item of Media coverage
Press/Media
-
Children's National Hospital becomes part of the national CAUSE Clinical Research Network under a $3 million grant
Paula Busse & Supinda Bunyavanich
26/04/21
1 item of Media coverage
Press/Media
-
NIH awards $10 million in first-year funding to establish clinical research network called CAUSE
26/04/21
2 items of Media coverage
Press/Media
-
NIH establishes new childhood asthma clinical research network
23/04/21 → 24/04/21
4 items of Media coverage
Press/Media
-